RadNet Reports Record Fourth Quarter and Full Year

• For the fourth quarter, RadNet reports record Total Net Revenue (“Revenue”) of $224.9 million, an increase of 4.3% over the prior year’s fourth quarter; Adjusted EBITDA ⁽¹⁾ was $34.9 million, the Company’s best performance in any fourth quarter, an increase of 7.2% over the same period in 2015
• For full year 2016, RadNet reports record Revenue of $884.5 million and record Adjusted EBITDA ⁽¹⁾ of $133.0 million, both increases of 9.3% as compared with full year 2015
• Net Income Attributable to RadNet, Inc. Common Stockholders (“Net Income”) for the fourth quarter was $3.7 million (or $0.08 per diluted share), compared to Net Income of $881 thousand (or $0.02 per diluted share) in the fourth quarter of 2015
• For full year 2016, Net Income was $7.2 million (or $0.15 per diluted share), compared with Net Income of $7.7 million (or $0.17 per diluted share) in 2015
• In the fourth quarter, same center advanced modalities (MRI, CT and PET/CT) increased 1.7%, driving same center Revenue to increase 2.8% over last year’s fourth quarter
• RadNet announces 2017 guidance ranges, anticipating increases in Revenue and Adjusted EBITDA ⁽¹⁾

LOS ANGELES, March 14, 2017 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT ) , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 305 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter and full year ended December 31, 2016.

Financial Results

Fourth Quarter Report:

For the fourth quarter of 2016, RadNet reported Revenue of $224.9 million, Adjusted EBITDA ⁽¹⁾ of $34.9 million and Net Income of $3.7.  Revenue increased $9.2 million (or 4.3%), Adjusted EBITDA ⁽¹⁾ increased $2.3 million (or 7.2%) and Net Income increased $2.8 million over the fourth quarter of 2015. 

Net Income for the fourth quarter was $0.08 per diluted share, compared to a Net Income of $0.02 per diluted share in the fourth quarter of 2015.  These per share values are based upon a weighted average number of diluted shares outstanding of 46.4 million in the fourth quarter of 2016 and 46.5 million of diluted shares outstanding in the fourth quarter of 2015.

Affecting Net Income in the fourth quarter of 2016 were certain non-cash expenses and non-recurring items including:  $908,000 of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $349,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $392,000 loss on the disposal of certain capital equipment; and $801,000 of amortization and write off of deferred financing costs and loan discount related to our existing credit facilities.

For the fourth quarter of 2016, as compared with the prior year’s fourth quarter, MRI volume increased 2.6%, CT volume increased 3.1% and PET/CT volume increased 4.0%.  Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 0.6% over the prior year’s fourth quarter.  On a same-center basis, including only those centers which were part of RadNet for both the fourth quarters of 2016 and 2015, MRI volume increased 1.5%, CT volume increased 1.7% and PET/CT volume increased 4.0%.  Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, was flat over the prior year’s same quarter.

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented “I am very pleased with our fourth quarter results.  As compared with last year’s same quarter, aggregate Revenue, EBITDA, Net Income and procedural volumes increased.  Our same center advanced modalities and Revenue also grew in the current quarter over last year’s fourth quarter.  Although we are not complete with our efforts, during the quarter we made significant progress in integrating our recently acquired operations of Diagnostic Imaging Group and New York Radiology Partners. These efforts included migrating billing and site-level clinical systems, evaluating, training and enhancing the capabilities of personnel, revamping marketing and branding strategies and migrating supply relationships and vendor contracts.”

Annual Report:

For full year 2016, the Company reported Revenue of $884.5 million, Adjusted EBITDA ⁽¹⁾ of $133.0 million and Net Income of $7.2 million.  Revenue increased $74.9 million (or 9.3%) and Adjusted EBITDA ⁽¹⁾ increased $11.4 million (or 9.3%).  Net Income for 2016 was $0.15 per diluted share, compared to Net Income of $0.17 per diluted share in 2015 (based upon a weighted average number of diluted shares outstanding of 46.7 million and 45.2 million in 2016 and 2015, respectively).

Affecting Net Income in 2016 were certain non-cash expenses and non-recurring items including:  $5.8 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $2.9 of severance paid in connection with headcount reductions related to cost savings initiatives; $767,000 loss on the disposal of certain capital equipment; $5.0 million gain on the return of common stock related to one of our acquisitions; and $5.0 million of amortization and write off of deferred financing fees and discount on issuance of debt related to our existing credit facilities and refinancing transaction.

For the year ended December 31, 2016, as compared to 2015, MRI volume increased 7.8%, CT volume increased 7.9% and PET/CT volume increased 7.9%.  Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 8.3% for the twelve months of 2016 over 2015.

“During 2016, we focused on internal operations and completed no material acquisitions.  I’m proud of our many operational and financial accomplishments during the year.  First, throughout 2016, we materially improved our balance sheet and financial leverage ratios.  We generated over $35 million of free cash flow, ended the year with a cash balance of over $20 million and reduced our net debt by over $20 million as compared with its balance on December 31, 2015.  We were able to significantly reduce our Net Debt to EBITDA leverage to 4.8x, down from 5.3x just one year ago,” concluded Dr. Berger.

“Another key accomplishment in 2016 was the announcement of our first West Coast health system joint venture with Dignity Health in Glendale, CA.  We are now fully operational with the two centers we own jointly.  We are actively working on additional health system partnerships on both coasts and look forward to announcing their successful formation during 2017.  Also during 2016, we laid the foundation to bring our West Coast Breastlink operations to two of our larger East Coast markets.  Throughout the year, we assembled the team, business plan and site locations for a comprehensive breast disease management offering we expect to become fully operational in the second quarter of 2017,” added Dr. Berger

“Additionally, subsequent to quarter end, we successfully completed an amendment to our senior credit facilities which reduced our interest rate by 0.5% on our $478.9 million senior secured first lien term loan and $117.5 million senior secured revolving credit facility.  This amounts to approximately $2.4 million of interest expense savings, providing additional cash flow which we will use to further de-lever our balance sheet or expand our business.”

Actual Results vs. 2016 Guidance:

The following compares the Company’s actual 2016 performance with previously announced revised guidance levels.

(a) Note the change from prior years.  This metric is now after the subtraction of bad debt. (b) Net of proceeds from the sale of equipment, imaging centers and joint venture interests. (c) Defined by the Company as Adjusted EBITDA ⁽¹⁾ less total capital expenditures and cash paid for interest.

2017 Fiscal Year Guidance

For its 2017 fiscal year, RadNet announces its guidance ranges as follows:

(a) Net of proceeds from the sale of equipment, imaging centers and joint venture interests. (b) Defined by the Company as Adjusted EBITDA ⁽¹⁾ less total capital expenditures and cash paid for interest.

Dr. Berger commented, “We have many reasons to be optimistic about 2017.  First, 2017 is the second year since 2006 that we will avoid a negative reimbursement impact from Medicare.  Second, we will complete the vast majority of integration efforts related to New York Radiology Partners and Diagnostic Imaging Group acquisitions.  Third, we will be launching Breastlink operations in two of our East Coast regions.  Fourth, we expect additional Revenue in 2017 from our continued adoption of 3D breast imaging.  And, lastly, we expect to begin operations in 2017 of new health system joint ventures.”

Conference Call for Today

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call today, at 10:30 a.m. Eastern Time.  During the call, management will discuss the Company's 2016 fourth quarter and year-end results.

Conference Call Details:

Date:  Tuesday, March 14, 2017 Time:  10:30 a.m. ET Dial In-Number:  888-801-6507 International Dial-In Number:  913-312-0660

There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=123283  or http://www.radnet.com under the “About RadNet” menu section and “News & Press Releases” sub-menu of the website.  An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 2430393.

Regulation G: GAAP and Non-GAAP Financial Information

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results.  The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance.  The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters.  Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies.  Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP.  Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of 305 owned and/or operated outpatient imaging centers.  RadNet's core markets include California, Maryland, Delaware, New Jersey, New York and Rhode Island. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 7,300 employees. For more information, visit http://www.radnet.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning successfully integrating the Company’s acquired operations, successfully achieving 2017 financial guidance, achieving cost savings, successfully developing and integrating its information technology operations as well as new lines of business, continuing to grow its business by generating patient referrals and contracts with radiology practices and receiving third-party reimbursement for diagnostic imaging services are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect RadNet's business and its financial results are detailed in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speak only as of the date they are made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Footnotes

⁽¹⁾ The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, bargain purchase gains and non-cash equity compensation.  Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash and extraordinary events which took place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure.  Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt.  Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

⁽²⁾ As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid.  Free Cash Flow is a non-GAAP financial measure.  The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

CONTACTS: RadNet, Inc. Mark Stolper, 310-445-2800 Executive Vice President and Chief Financial Officer